A Study of Aleglitazar in Patients With Type 2 Diabetes
This study has been completed.
Information provided by (Responsible Party):
First received: October 16, 2006
Last updated: November 1, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||March 2008|
|Primary Completion Date:||March 2008 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||June 28, 2016|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009 Jul 11;374(9684):126-35. doi: 10.1016/S0140-6736(09)60870-9.